These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22159702)

  • 21. Cancer care, money, and the value of life: whose justice? Which rationality?
    Sulmasy DP
    J Clin Oncol; 2007 Jan; 25(2):217-22. PubMed ID: 17210943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palliative care for the terminally ill in America: the consideration of QALYs, costs, and ethical issues.
    Yang YT; Mahon MM
    Med Health Care Philos; 2012 Nov; 15(4):411-6. PubMed ID: 22071573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.
    Bourbeau J; Granados D; Roze S; Durand-Zaleski I; Casan P; Köhler D; Tognella S; Viejo JL; Dal Negro RW; Kessler R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():645-657. PubMed ID: 30936689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neuropharmacoeconomics].
    Chiu HC
    Acta Neurol Taiwan; 2004 Jun; 13(2):87-96. PubMed ID: 15478681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost per quality-adjusted life year gained of revision neural decompression and instrumented fusion for same-level recurrent lumbar stenosis: defining the value of surgical intervention.
    Adogwa O; Parker SL; Shau DN; Mendenhall SK; Aaronson O; Cheng JS; Devin CJ; McGirt MJ
    J Neurosurg Spine; 2012 Feb; 16(2):135-40. PubMed ID: 22054639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inquiry into the relationship between equity weights and the value of the QALY.
    Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2012 Dec; 15(8):1119-26. PubMed ID: 23244815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding quality-adjusted life years and their application to pharmacoeconomic research.
    Raisch DW
    Ann Pharmacother; 2000; 34(7-8):906-14. PubMed ID: 10928403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
    Garrison LP; Veenstra DL
    Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health outcomes in economic evaluation: the QALY and utilities.
    Whitehead SJ; Ali S
    Br Med Bull; 2010; 96():5-21. PubMed ID: 21037243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Problems and solutions in calculating quality-adjusted life years (QALYs).
    Prieto L; Sacristán JA
    Health Qual Life Outcomes; 2003 Dec; 1():80. PubMed ID: 14687421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncological resource allocation in Germany.
    Hartmann M; Kath R; Gundermann C
    Onkologie; 2008 Mar; 31(3):85-9. PubMed ID: 18322410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost per quality-adjusted life year gained of laminectomy and extension of instrumented fusion for adjacent-segment disease: defining the value of surgical intervention.
    Adogwa O; Parker SL; Shau DN; Mendenhall SK; Devin CJ; Cheng JS; McGirt MJ
    J Neurosurg Spine; 2012 Feb; 16(2):141-6. PubMed ID: 22054637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.